1188 related articles for article (PubMed ID: 35451807)
1. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
[TBL] [Abstract][Full Text] [Related]
3. Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice.
Zamani-Garmsiri F; Ghasempour G; Aliabadi M; Hashemnia SMR; Emamgholipour S; Meshkani R
IUBMB Life; 2021 Jan; 73(1):252-263. PubMed ID: 33326684
[TBL] [Abstract][Full Text] [Related]
4. JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRT1/NF-κB pathway in high-fat-diet-fed C57BL/6 mice.
Tian J; Cai M; Jin S; Chen Q; Xu J; Guo Q; Yan Z; Han X; Lu H
Pharm Biol; 2023 Dec; 61(1):647-656. PubMed ID: 37038833
[TBL] [Abstract][Full Text] [Related]
5. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
Tian X; Xiong Q; Chen L; Wen JR; Ru Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
[No Abstract] [Full Text] [Related]
6. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.
Ren J; Wang X; Yee C; Gorrell MD; McLennan SV; Twigg SM
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163991
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice.
Goodarzi G; Tehrani SS; Panahi G; Bahramzadeh A; Meshkani R
J Nutr Biochem; 2023 Aug; 118():109369. PubMed ID: 37100305
[TBL] [Abstract][Full Text] [Related]
9. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
[TBL] [Abstract][Full Text] [Related]
10. Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
Zou W; Zhang C; Gu X; Li X; Zhu H
Drug Des Devel Ther; 2021; 15():2565-2576. PubMed ID: 34168429
[TBL] [Abstract][Full Text] [Related]
11. Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study.
Heeba GH; El-Deen RM; Abdel-Latif RG; Khalifa MMA
Can J Physiol Pharmacol; 2020 Aug; 98(8):498-505. PubMed ID: 32083947
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice.
He C; Cheng D; Wang H; Wu K; Zhu Y; Lu N
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):360-367. PubMed ID: 29657020
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
14. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
[No Abstract] [Full Text] [Related]
15. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
[TBL] [Abstract][Full Text] [Related]
16. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
17. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
18. Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.
Wahlang B; Falkner KC; Gregory B; Ansert D; Young D; Conklin DJ; Bhatnagar A; McClain CJ; Cave M
J Nutr Biochem; 2013 Sep; 24(9):1587-95. PubMed ID: 23618531
[TBL] [Abstract][Full Text] [Related]
19. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
20. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
